Cytokines as biomarkers in depressive disorder: Current standing and prospects

References

• Abbasi, S.H., Hosseini, F., Modabbernia, A., Ashrafi, M. & Akhondzadeh, S. (2012). Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study. Journal of Affective Disorders, 141, 308–314.
   PubMed Web of Science ®Google Scholar
• Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A.A., Ghoreishi, A., Salehi, B., … Kamalipour, A. (2009). Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. Journal of Depression and Anxiety, 26, 607–611.
   PubMed Web of Science ®Google Scholar
• Antonioli, M., Rybka, J. & Carvalho, L.A. (2012). Neuroimmune endocrine effects of antidepressants. Neuropsychiatric Disease and Treatment, 8, 65–83.
   PubMed Web of Science ®Google Scholar
• Argaw, A.T., Asp, L., Zhang, J., Navrazhina, K., Pham, T., Mariani, J.N., … John, G.R. (2012). Astrocyte-derived VEGF-A drives blood–brain barrier disruption in CNS inflammatory disease. Journal of Clinical Investigation, 122, 2454–2468.
   PubMed Web of Science ®Google Scholar
• Banks, W.A. (2001). Anorectic effects of circulating cytokines: Role of the vascular blood–brain barrier. Nutrition, 17, 434–437.
   PubMedGoogle Scholar
• Bano, S., Gitay, M., Ara, I. & Badawy, A. (2010). Acute effects of serotonergic antidepressants on tryptophan metabolism and corticosterone levels in rats. Pakistan Journal of Pharmaceutical Sciences, 23, 266–272.
   PubMed Web of Science ®Google Scholar
• Bano, S., Morgan, C.J., Badawy, A.A.B., Buckland, P.R. & McGuffin, P. (1999). Inhibition of rat liver tryptophan pyrrolase activity by fluoxetine. Pakistan Journal of Pharmaceutical Sciences, 12, 11–16.
   PubMedGoogle Scholar
• Bauer, M., Adli, M., Bschor, T., Pilhatsch, M., Pfennig, A., Sasse, J., … Lewitzka, U. (2010). Lithium's emerging role in the treatment of refractory major depressive episodes: Augmentation of antidepressants. Neuropsychobiology, 62, 36–42.
   PubMed Web of Science ®Google Scholar
• Baune, B.T., Dannlowski, U., Domschke, K., Janssen, D.G., Jordan, M.A., Ohrmann, P., … Suslow T. (2010). The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biological Psychiatry, 67, 543–549.
   PubMed Web of Science ®Google Scholar
• Belanoff, J.K., Rothschild, A.J., Cassidy, F., Debattista, C., Baulieu, E.E., Schold, C. & Schatzberg, A.F. (2002). An open label trial of C-1073 (mifepristone) for psychotic major depression. Biological Psychiatry, 52, 386–392.
   PubMed Web of Science ®Google Scholar
• Benedetti, F., Campori, E., Colombo, C. & Smeraldi, E. (2004). Fluvoxamine treatment of major depression associated with multiple sclerosis. Journal of Neuropsychiatry and Clinical Neurosciences, 16, 364–366.
   PubMed Web of Science ®Google Scholar
• Berthold-Losleben, M. & Himmerich, H. (2008). The TNF- alpha system: Functional aspects in depression, narcolepsy and psychopharmacology. Current Neuropharmacology, 6, 193–202.
   PubMed Web of Science ®Google Scholar
• Besedovsky, H.O., del Rey, A., Klusman, I., Furukawa, H., Monge Arditi, G. & Kabiersch, A. (1991). Cytokines as modulators of the hypothalamus–pituitary–adrenal axis. Journal of Steroid Biochemistry and Molecular Biology, 40, 613–618.
   PubMed Web of Science ®Google Scholar
• Bluthé, R.M., Michaud, B., Kelley, K.W. & Dantzer, R. (1996). Vagotomy attenuates behavioural effects of interleukin-1 injected peripherally but not centrally. Neuroreport, 7, 1485–1488.
   PubMed Web of Science ®Google Scholar
• Bluthé, R.M., Walter, V., Parnet, P., Layé, S., Lestage, J. & Verrier, D., … Dantzer, R. (1994). Lipopolysaccharide induces sickness behaviour in rats by a vagal mediated mechanism. Comptes Rendus de l’Académie des Sciences, 317, 499–503.
   PubMed Web of Science ®Google Scholar
• Bromet, E., Andrade, L.H., Hwang, I., Sampson, N.A., Alonso, J., de Girolamo, G. … Kessler, R.C. (2011). Cross-national epidemiology of DSM-IV major depressive episode. BMC Medicine, 9, 90.
   PubMed Web of Science ®Google Scholar
• Capuron, L. & Miller, A.H. (2011). Immune system to brain signaling: Neuropsychopharmacological implications. Pharmacology and Therapeutics, 130, 226–238.
   PubMed Web of Science ®Google Scholar
• Carpenter, L.L., Heninger, G.R., Malison, R.T., Tyrka, A.R. & Price, L.H. (2004). Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. Journal of Affective Disorders, 79, 285–289.
   PubMed Web of Science ®Google Scholar
• Chang, H.D. & Radbruch, A. (2007). The pro- and anti-inflammatory potential of interleukin-12. Annals of the New York Academy of Sciences, 1109, 40–46.
   PubMedGoogle Scholar
• Chiaravalloti, N.D. & Deluca, J. (2008). Cognitive impairment in multiple sclerosis. Lancet Neurology, 7, 1139–1151.
   PubMed Web of Science ®Google Scholar
• da Silva, A.M., Vilhena, E., Lopes, A., Santos, E., Gonçalves, M.A., Pinto C., .. Cavaco, S. (2011). Depression and anxiety in a Portuguese MS population: Associations with physical disability and severity of disease. Journal of the Neurological Sciences, 306, 66–70.
   PubMedGoogle Scholar
• Dantzer, R. (2009). Cytokine, sickness behavior, and depression. Immunology and Allergy Clinics of North America, 29, 247–264.
   PubMed Web of Science ®Google Scholar
• Di Costanzo, L., Ayala, F., Megna, M., Gaudiello, F., Patrì, A. & Balato. N. (2013). The risk of herpes zoster in the anti- TNF-α era: A case report and review of the literature. Journal of Dermatology Case Reports, 7, 1–4.
   PubMedGoogle Scholar
• Domingues, H.S., Mues, M., Lassmann, H., Wekerle, H. & Krishnamoorthy, G. (2010). Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. PLoS One, 5, 15531.
   PubMed Web of Science ®Google Scholar
• Eller, T., Aluoja, A., Maron, E. & Vasar, V. (2009). Soluble interleukin-2 receptor and tumor necrosis factor levels in depressed patients in Estonia. Medicina (Kaunas), 45, 971–977.
   PubMedGoogle Scholar
• Eller, T., Vasar, V., Shlik, J. & Maron, E. (2008)Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32, 445–450.
   PubMed Web of Science ®Google Scholar
• Erhardt, S., Lim, C.K., Linderholm, K.R., Janelidze, S., Lindqvist, D., Samuelsson, M., … Brundin, L. (2013). Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology, 38, 743–752.
   PubMed Web of Science ®Google Scholar
• Ericsson, A., Kovacs, K.J. & Sawchenko, P.E. (1994). A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. Journal of Neuroscience, 14, 897–913.
   PubMed Web of Science ®Google Scholar
• Feinstein, A. (2000). Multiple sclerosis, disease modifying treatments and depression: A critical methodological review. Multiple Sclerosis Journal, 6, 343–348.
   PubMedGoogle Scholar
• Feinstein, A. (2004). The neuropsychiatry of multiple sclerosis. Canadian Journal of Psychiatry, 49, 157–163.
   PubMed Web of Science ®Google Scholar
• Feinstein, A., O’Connor, P. & Feinstein, K. (2002). Multiple sclerosis, interferon beta-1b and depression: A prospective investigation. Journal of Neurology, 249, 815–820.
   PubMed Web of Science ®Google Scholar
• Fluitman, S.B., Heijnen, C.J., Denys, D.A., Nolen, W.A., Balk, F.J. & Westenberg, H.G. (2011). Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder. Journal of Affective Disorders, 131, 388–392.
   PubMed Web of Science ®Google Scholar
• Foley, F.W., Traugott, U., La Rocca, N.G., Smith, C.R., Perlman, K.R., Caruso, L.S. & Scheinberg, L.C. (1992). A prospective study of depression and immune dysregulation in multiple sclerosis. Archives of Neurology, 49, 238–244.
   PubMed Web of Science ®Google Scholar
• Fuchs, E. & Flügge, G. (2005). Eine Störung der Neuroplastizität? [A disorder of neuroplasticity?] Psychoneuroimmunologie, 31, 197–203.
   PubMedGoogle Scholar
• Gill, J., Luckenbaugh, D., Charney, D. & Vythilingam, M. (2010). Sustained elevation of serum interleukin-6 and relative insensitivity to hydrocortisone differentiates posttraumatic stress disorder with and without depression. Biological Psychiatry, 68, 999–1006.
   PubMedGoogle Scholar
• Girgenti, M.J., Hunsberger, J., Duman, C.H., Sathyanesan, M., Terwilliger, R. & Newton, S.S. (2009). Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects. Biological Psychiatry, 66, 267–274.
   PubMed Web of Science ®Google Scholar
• Goldman Consensus Group. (2005). The Goldman Consensus statement on depression in multiple sclerosis. Multiple Sclerosis Journal, 11, 328–337.
   PubMed Web of Science ®Google Scholar
• Halperin, D. & Reber, G. (2007). Influence of antidepressants on hemostasis. Dialogues in Clinical Neuroscience, 9, 47–59.
   PubMedGoogle Scholar
• Heiser, P., Lanquillon, S., Krieg, J.C. & Vedder, H. (2008). Differential modulation of cytokine production in major depressive disorder by cortisol and dexamethasone. European Neuropsychopharmacology, 18, 860–870.
   PubMedGoogle Scholar
• Himmerich, H., Berthold-Losleben, M. & Pollmächer, T. (2009). The relevance of the TNF-alpha system in psychiatric disorders. Fortschritte der Neurologie – Psychiatrie, 77, 334–345.
   PubMed Web of Science ®Google Scholar
• Himmerich, H., Fulda, S., Linseisen, J., Seiler, H., Wolfram, G., Himmerich S., … Pollmächer, T. (2008). Depression, comorbidities and the TNF-alpha system. European Psychiatry, 23, 421–429.
   PubMed Web of Science ®Google Scholar
• Himmerich, H., Fulda, S., Sheldrick, A.J., Plümäkers, B. & Rink, L. (2010b). IFN-gamma reduction by tricyclic antidepressants. International Journal of Psychiatry in Medicine, 40, 413–424.
   PubMedGoogle Scholar
• Himmerich, H., Koethe, D., Schuld, A., Yassouridis, A. & Pollmächer, T. (2005). Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology, 179, 447–451.
   PubMedGoogle Scholar
• Himmerich, H., Milenović, S., Fulda, S., Plümäkers, B., Sheldrick, A.J., Michel, T.M., … Rink, L. (2010a). Regulatory T cells increased while IL-1β decreased during antidepressant therapy. Journal of Psychiatric Research, 44, 1052–1057.
   PubMedGoogle Scholar
• Himmerich, H. & Sheldrick, A.J. (2010). TNF-alpha and ghrelin: Opposite effects on immune system, metabolism and mental health. Protein and Peptide Letters, 17, 186–196.
   PubMed Web of Science ®Google Scholar
• Himmerich, H., Sorge, S., Kirkby, K.C. & Steinberg, H. (2012). Schizophrenic disorders. The development of immunological concepts and therapy in psychiatry. Nervenarzt, 83, 7–15.
   PubMedGoogle Scholar
• Himmerich, H. & Wranik, D.W. (2012). Choice of treatment with antidepressants: Influencing factors. Current Pharmaceutical Design, 18, 5958–5975.
   PubMed Web of Science ®Google Scholar
• Hinze-Selch, D., Schuld, A., Kraus, T., Kühn, M., Uhr, M., Haack, M. & Pollmächer T (2000). Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology, 23, 13–19.
   PubMed Web of Science ®Google Scholar
• Janelidze, S., Ventorp, F., Erhardt, S., Hansson, O., Minthon, L. Flax, J., … Brundin, L. (2012). Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. Psychoneuroendocrinology. doi: 10.1016/j.psyneuen.2012.09.010
   PubMedGoogle Scholar
• Joffe, R.T., Lippert, G.P., Gray, T.A., Sawa, G. & Horwath, Z. (1987). Mood disorders and multiple sclerosis. Archives of Neurology, 44, 376–378.
   PubMed Web of Science ®Google Scholar
• Jokinen, J., Chatzittofis, A., Hellström, C., Nordström, P., Uvnäs-Moberg, K. & Asberg, M. (2012). Low CSF oxytocin reflects high intent in suicide attempters. Psychoneuroendocrinology, 37, 482–490.
   PubMedGoogle Scholar
• Kawaguchi, R., Shimokawa, T., Umehara, N., Nunomura, S., Tanaka, T. & Ra, C. (2008). Priming of peripheral monocytes with prolactin (PRL) sensitizes IFN-gamma-mediated indoleamine 2,3-dioxygenase (IDO) expression without affecting IFN-gamma signaling. Journal of Reproductive Immunology, 77, 117–125.
   PubMedGoogle Scholar
• Khosro, S., Alireza, S., Omid, A. & Forough, S. (2011). Night work and inflammatory markers. Indian Journal of Occupational and Environmental Medicine, 15, 38–41.
   PubMedGoogle Scholar
• Kiank, C., Zeden, J.P., Drude, S., Domanska, G., Fusch, G., Otten, W. & Schuett, C. (2010). Psychological stress-induced, IDO1-dependent tryptophan catabolism: Implications on immunosuppression in mice and humans. PLoS One, 5, e11825.
   PubMed Web of Science ®Google Scholar
• Kim, Y.K., Na, K.S., Shin, K.H., Jung, H.Y., Choi, S.H. & Kim, J.B. (2007). Cytokine imbalance in the pathophysiology of major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31, 1044–1033.
   PubMed Web of Science ®Google Scholar
• Koch, M.W., Glazenborg, A., Uyttenboogaart, M., Mostert, J. & De Keyser, J. (2011). Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database of Systematic Reviews, CD007295.
   Google Scholar
• Kraus, T., Haack, M., Schuld, A., Hinze-Selch, D., Koethe, D. & Pollmächer, T. (2002). Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry, 35, 220–225.
   PubMed Web of Science ®Google Scholar
• Krügel, U., Fischer, J., Radicke, S., Sack, U. & Himmerich, H. (2013). Antidepressant effects of TNF-α blockade in an animal model of depression. Journal of Psychiatric Research, 47, 611–616.
   PubMedGoogle Scholar
• Kuhn R. (1958). The treatment of depressive states with G 22355 (imipramine hydrochloride). American Journal of Psychiatry, 115, 459–464.
   PubMed Web of Science ®Google Scholar
• Lanquillon, S., Krieg, J.-C., Bening-Abu-Shach, U. & Vedder, H. (2000). Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology, 22, 370–379.
   PubMed Web of Science ®Google Scholar
• Leucht, C., Huhn, M., Leucht, S. (2012). Amitriptyline versus placebo for major depressive disorder. Cochrane Database of Systematic Reviews, CD009138.
   Google Scholar
• Li, X., Cudaback, E., Breyer, R.M., Montine, K.S., Keene, C.D. & Montine, T.J. (2012). Eicosanoid receptor subtype-mediated opposing regulation of TLR-stimulated expression of astrocyte glial-derived neurotrophic factor. FASEB Journal, 26, 3075–3083.
   PubMed Web of Science ®Google Scholar
• Lichtblau, N., Schmidt, F. & Himmerich, H. (2012). Die Rolle von Zytokinen bei psychiatrischen Erkrankungen – Immunsystem und Depression [Influences of cytokines on psychiatric disorders - the immune system and depression]. InFo Neurologie Psychiatrie, 14, 56–62.
   Google Scholar
• Lindqvist, D., Janelidze, S., Erhardt, S., Träskman-Bendz, L., Engström, G. & Brundin, L. (2011). CSF biomarkers in suicide attempters – A principal component analysis. Acta Psychiatrica Scandinavica, 124, 52–61.
   PubMed Web of Science ®Google Scholar
• Lindqvist, D., Janelidze, S., Hagell, P., Erhardt, S., Samuelsson, M., Minthon, L., … Brudin, L. (2009). Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biological Psychiatry, 66, 287–292.
   PubMed Web of Science ®Google Scholar
• Ljung, L., Smeds, J., Persson, G., Jirlén, L. & Toolanen, G. (2012). Immunosuppression may mask severe infection. Septic arthritis in tocilizumab treatment yielded only modest acute-phase reaction. Lakartidningen, 109, 1678–1679.
   PubMedGoogle Scholar
• Loser, K. & Beissert, S. (2007). Dendritic cells and T cells in the regulation of cutaneous immunity. Advances in Dermatology, 23, 307–333.
   PubMedGoogle Scholar
• Lotrich F. (2012). Inflammatory cytokines, growth factors, and depression. Current Pharmaceutical Design, 18, 5920–5935.
   PubMedGoogle Scholar
• Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E. & Neels, H. (1997). Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine, 9, 853–858.
   PubMed Web of Science ®Google Scholar
• Maes, M., Meltzer, H.Y., Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R & Desnyder, R. (1995). Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. Journal of Affective Disorders, 34, 301–309.
   PubMed Web of Science ®Google Scholar
• Malynn, S., Campos-Torres, A., Moynagh, P. & Haase, J. (2013). The pro-inflammatory cytokine TNF-α regulates the activity and expression of the serotonin transporter (SERT) in astrocytes. Neurochemical Research, 38, 694–704.
   PubMed Web of Science ®Google Scholar
• Martinez, J.M., Garakani, A., Yehuda, R. & Gorman, J.M. (2012). Proinflammatory and ‘resiliency’ proteins in the CSF of patients with major depression. Depression and Anxiety, 29, 32–38.
   PubMed Web of Science ®Google Scholar
• Mattox, J.H., Buckman, M.T., Bernstein, J., Pathak, D. & Kellner, R. (1986). Dopamine agonists for reducing depression associated with hyperprolactinemia. Journal of Reproductive Medicine, 31, 694–698.
   PubMed Web of Science ®Google Scholar
• McIvor, G.P., Riklan, M. & Reznikoff, M. (1984). Depression in multiple sclerosis as a function of length and severity of illness, age, remission and perceived social support. Journal of Clinical Psychology, 40, 1028–1033.
   PubMed Web of Science ®Google Scholar
• Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S. & Brunello, N. (2006). Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: A pilot open-label study. International Clinical Psychopharmacology, 21, 227–231.
   PubMed Web of Science ®Google Scholar
• Merrill, J.E. (1992). Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. Developmental Neuroscience, 14, 1–10.
   PubMedGoogle Scholar
• Mitsonis, C.I., Zervas, I.M., Potagas, C.M., Mitropoulos, P.A., Dimopoulos, N.P., Sfagos, C.A. … Vassilopoulos, D.C. (2010). Effects of escitalopram on stress-related relapses in women with multiple sclerosis: An open-label, randomized, controlled, one-year follow-up study. European Neuropsychopharmacology, 20, 123–131.
   PubMedGoogle Scholar
• Modabbernia, A., Taslimi, S., Brietzke, E. & Ashrafi, M. (2013). Cytokine alterations in bipolar disorder: A meta-analysis of 30 studies. Biological Psychiatry. doi: 10.1016/j.biopsych.2013.01.007
   PubMedGoogle Scholar
• Mohr, D.C., Boudewyn, A.C., Goodkin, D.E., Bostrom, A. & Epstein, L. (2001). Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. Journal of Consulting and Clinical Psychology, 69, 942–949.
   PubMed Web of Science ®Google Scholar
• Mohr, D.C., Hart, S.L., Fonavera, I. & Tasch, E.S. (2006). Treatment of depression for patients with multiple sclerosis in neurology clinics. Multiple Sclerosis Journal, 12, 204–208.
   PubMed Web of Science ®Google Scholar
• Mohr, D.C., Hart, S.L., Julian, L., Catledge, C., Honos-Webb, L., Vella, L. & Tasch, E.T. (2005). Telephone-administered psychotherapy for depression. Archives of General Psychiatry, 62, 1007–1014.
   PubMed Web of Science ®Google Scholar
• Mostert, J.P., Admiraal-Behloul, F., Hoogduin, J.M., Luyendijk, J., Heersema, D.J., van Buchem, M.A. & De Keyser, J. (2008). Effects of fluoxetine on disease activity in relapsing multiple sclerosis: A double-blind, placebo-controlled, exploratory study. Journal of Neurology, Neurosurgery and Psychiatry, 79, 1027–1031.
   PubMedGoogle Scholar
• Müller, N. & Schwarz, M.J. (2007). Immunologische Aspekte bei depressiven Störungen [Immunological aspects of depressive disorders]. Nervenarzt, 78, 1261–1273.
   PubMedGoogle Scholar
• Müller, N., Schwarz, M.J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., … Riedel, M. (2006). The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular Psychiatry, 11, 680–684.
   PubMed Web of Science ®Google Scholar
• Musgrave, T., Benson, C., Wong, G., Browne, I., Tenorio, G., Rauw, G., … Kerr, B.J. (2011). The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain, Behavior, and Immunity, 25, 1677–1688.
   PubMed Web of Science ®Google Scholar
• Nakata, A., Haratani, T., Takahashi, M., Kawakami, N., Arito, H., Kobayashi F., .. Araki, S. (2004). Association of sickness absence with poor sleep and depressive symptoms in shift workers. Chronobiology International, 21, 899–912.
   PubMed Web of Science ®Google Scholar
• Pålhagen, S., Qi, H., Mårtensson, B., Wålinder, J., Granérus, A.K. & Svenningsson, P. (2010). Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. Journal of Neurology, 257, 524–532.
   PubMedGoogle Scholar
• Pandey, G.N., Rizavi, H.S., Ren, X., Fareed, J., Hoppensteadt, D.A., Roberts, R.C., … Dwivedi, Y. (2011). Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. Journal of Psychiatric Research, 46, 57–63.
   PubMedGoogle Scholar
• Patten, S.B., Williams, J.V. & Love, E.J. (1995). A case-control study of corticosteroid exposure as a risk factor for clinically-diagnosed depressive disorders in a hospitalized population. Canadian Journal of Psychiatry, 40, 396–400.
   PubMedGoogle Scholar
• Peck, A. & Mallins, E.D. (2009). Plasticity of T-cell phenotype and function: The T helper type 17 example. Immunology, 129, 147–153.
   PubMed Web of Science ®Google Scholar
• Penninx, B.W., Kritchevsky, S.B., Yaffe, K., Newman, A.B., Simonsick, E.M., Rubin, S., … Pahor, M. (2003). Inflammatory markers and depressed mood in older persons: Results from the Health, Aging and Body Composition study. Biological Psychiatry, 54, 566–572.
   PubMed Web of Science ®Google Scholar
• Pincus, H.A. & Pettit, A.R. (2001)The societal costs of chronic major depression. Journal of Clinical Psychiatry, 62(S6), S5–9.
   Google Scholar
• Price, A., Rayner, L., Okon-Rocha, E., Evans, A., Valsraj, K., Higginson, I.J. & Hotopf, M. (2011). Antidepressants for the treatment of depression in neurological disorders: A systematic review and meta-analysis of randomised controlled trials. Journal of Neurology, Neurosurgery and Psychiatry, 82, 914–923.
   PubMed Web of Science ®Google Scholar
• Ramamoorthy, S., Ramamoorthy, J.D., Prasad, P.D., Bhat, G.K., Mahesh, V.B., Leibach, F.H. & Ganapathy, V. (1995). Regulation of the human serotonin transporter by interleukin-1 beta. Biochemical and Biophysical Research Communications, 216, 560–567.
   PubMed Web of Science ®Google Scholar
• Rief, W., Mills, P.J., Ancoli-Israel, S., Ziegler, M.G., Pung, M.A. & Dimsdale, J.E. (2010). Overnight changes of immune parameters and catecholamines are associated with mood and stress. Psychosomatic Medicine, 72, 755–762.
   PubMedGoogle Scholar
• Rivera-Baltanas, T., Olivares, J.M., Calado-Otero, M., Kalynchuk, L.E., Martinez-Villamarin, J.R. & Caruncho, H.J. (2012). Serotonin transporter clustering in blood lymphocytes as a putative biomarker of therapeutic efficacy in major depressive disorder. Journal of Affective Disorders, 137, 46–55.
   PubMedGoogle Scholar
• Rothermundt, M., Arolt, V., Fenker, J., Gutbrodt, H., Peters, M. & Kirchner, H. (2001). Different immune patterns in melancholic and non-melancholic major depression. European Archives of Psychiatry and Clinical Neurosciences, 251, 90–97.
   PubMed Web of Science ®Google Scholar
• Sasayama, D., Hattori, K., Wakabayashi, C., Teraishi, T., Hori, H., Ota, M., … Kunugi, H. (2013). Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. Journal of Psychiatric Research, 47, 401–406.
   PubMed Web of Science ®Google Scholar
• Schildkraut, J.J. (1965). The catecholamine hypothesis of affective disorders: A review of supporting evidence. American Journal of Psychiatry, 122, 509–522.
   PubMed Web of Science ®Google Scholar
• Schumann, R., Adamaszek, M., Sommer, N. & Kirkby, K.C. (2012). Stress, depression and antidepressant treatment options in patients suffering from multiple sclerosis. Current Pharmaceutical Design, 18, 5837–5845.
   PubMedGoogle Scholar
• Scott, T.F., Nussbaum, P., McConnell, H. & Brill, P. (1995). Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Journal of Neurology Research, 17, 421–422.
   PubMed Web of Science ®Google Scholar
• Sijens, P.E., Mostert, J.P., Irwan, R., Potze, J.H., Oudkerk, M. & De Keyser, J. (2008). Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging. Psychiatry Research, 164, 274–282.
   PubMedGoogle Scholar
• Slaughter, J.R., Slaughter, K.A., Nichols, D., Holmes, S.E. & Martens, M.P. (2001). Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. Journal of Neuropsychiatry and Clinical Neurosciences, 13, 187–196.
   PubMed Web of Science ®Google Scholar
• Sokero, T.P., Melartin, T.K., Rytsälä, H.J., Leskelä, U.S., Lestelä-Mielonen, P.S. & Isometsä, E.T. (2003). Suicidal ideation and attempts among psychiatric patients with major depressive disorder. Journal of Clinical Psychiatry, 64, 1094–1100.
   PubMed Web of Science ®Google Scholar
• Steinberg, H. & Himmerich, H. (2012). Roland Kuhn – 100th birthday of an innovator of clinical psychopharmacology. Psychopharmacology Bulletin, 45, 48–50.
   PubMedGoogle Scholar
• Su, S., Miller, A.H., Snieder, H., Bremner, J.D., Ritchie, J., Maisano, C., … Vaccarino, V. (2009). Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: The Twins Heart Study. Psychosomatic Medicine, 71, 152–158.
   PubMed Web of Science ®Google Scholar
• Surget, A., Wang, Y., Leman, S., Ibarguen-Vargas, Y., Edgar, N., Griebel, G., … Sibille, E. (2009). Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology, 34, 1363–1380.
   PubMed Web of Science ®Google Scholar
• Surridge, D. (1969). An investigation into some psychiatric aspects of multiple sclerosis. British Journal of Psychiatry, 115, 749–764.
   PubMed Web of Science ®Google Scholar
• Taler, M., Gil-Ad, I., Korob, I. & Weizman, A. (2011). The immunomodulatory effect of the antidepressant sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Neuroimmunomodulation, 18, 117–122.
   PubMed Web of Science ®Google Scholar
• Thomas, A.J., Davis, S., Morris, C., Jackson, E., Harrison, R. & O’Brien, J.T. (2005). Increase in interleukin-1beta in late-life depression. American Journal of Psychiatry,162, 175–177.
   PubMed Web of Science ®Google Scholar
• Toh, S., Li, L., Harrold, L.R., Bayliss, E.A., Curtis, J.R., Liu, L., … Herrinton, L.J. (2012). Comparative safety of infliximab and etanercept on the risk of serious infections: Does the association vary by patient characteristics? Pharmacoepidemiology and Drug Safety, 21, 524–534.
   PubMedGoogle Scholar
• Tonelli, L.H., Stiller, J., Rujescu, D., Giegling, I., Schneider, B., Maurer, K., … Postolache, T.T. (2008). Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatrica Scandinavica, 117, 198–206.
   PubMed Web of Science ®Google Scholar
• Tsai, S.J. (2007). Glatiramer acetate could be a potential antidepressant through its neuroprotective and anti-inflammatory effects. Medical Hypotheses, 69, 145–148.
   PubMedGoogle Scholar
• Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., … Krishnan, R. (2006). Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double- blind placebo-controlled randomised phase III trial. Lancet, 367, 29–35.
   PubMed Web of Science ®Google Scholar
• Tzartos, J.S., Friese, M.A., Craner, M.J., Palace, J., Newcombe, J., Esiri, M.M. & Fugger, L. (2008). Interleukin-17 production in central nervous system-infiltrating T Cells and glial cells is associated with active disease in multiple sclerosis. American Journal of Pathology, 172, 146–155.
   PubMed Web of Science ®Google Scholar
• van Haelst, I.M., Egberts, T.C., Doodeman, H.J., Traast, H.S., Burger, B.J., Kalkman, C.J. & van Klei, W.A. (2010). Use of serotonergic antidepressants and bleeding risk in orthopedic patients. Anesthesiology, 112, 631–636.
   PubMed Web of Science ®Google Scholar
• Vgontzas, A.N., Zoumakis, E., Bixler, E.O., Lin, H.M., Follett, H., Kales, A. & Chrousos, G.P. (2004). Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. Journal of Clinical Endocrinology and Metabolism, 89, 2119–2126.
   PubMed Web of Science ®Google Scholar
• Vignali, D.A., Collison, L.W. & Workman, C.J. (2008). How regulatory T cells work. Nature Reviews Immunology, 8, 523–532.
   PubMed Web of Science ®Google Scholar
• Vollmar, P., Nessler, S., Kalluri, S.R., Hartung, H.P. & Hemmer, B. (2009). The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. International Journal of Neuropsychopharmacology, 12, 525–536.
   PubMedGoogle Scholar
• Waehrens, J. & Gerlach, J. (1981). Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients. Journal of Affective Disorders, 3, 193–202.
   PubMed Web of Science ®Google Scholar
• Warner-Schmidt, J.L., Vanover, K.E., Chen, E.Y., Marshall, J.J. & Greengard, P. (2011). Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proceedings of the National Academy of Sciences of the United States of America, 108, 9262–9267.
   PubMedGoogle Scholar
• Watanabe, N., Omori, I.M., Nakagawa, A., Cipriani, A., Barbui, C., Churchill, R. & Furukawa, T.A. (2011). Mirtazapine versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews, CD006528.
   PubMedGoogle Scholar
• Weschenfelder, J., Sander, C., Kluge, M., Kirkby, K.C. & Himmerich, H. (2012). The influence of cytokines on wakefulness regulation: clinical relevance, mechanisms and methodological problems. Psychiatria Danubina, 24, 112–126.
   PubMed Web of Science ®Google Scholar
• Yang, L., Zhang, Z., Sun, D., Xu, Z., Zhang, X. & Li, L. (2010). The serum interleukin-18 is a potential marker for development of post-stroke depression. Journal of Neurology Research, 32, 340–346.
   PubMed Web of Science ®Google Scholar
• Yoshimura, R., Hori, H., Ikenouchi-Sugita, A., Umene-Nakano, W., Ueda, N. & Nakamura, J. (2009). Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33, 722–726.
   PubMed Web of Science ®Google Scholar